Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Inhibition of UBE2L6 attenuates ISGylation and impedes ATRA-induced differentiation of leukemic cells.

Orfali N, Shan-Krauer D, O'Donovan TR, Mongan NP, Gudas LJ, Cahill MR, Tschan MP, McKenna SL.

Mol Oncol. 2019 Dec 10. doi: 10.1002/1878-0261.12614. [Epub ahead of print]

2.

All-trans retinoic acid (ATRA) induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).

Orfali N, O'Donovan TR, Cahill MR, Benjamin D, Nanus DM, McKenna SL, Gudas LJ, Mongan NP.

Eur J Haematol. 2019 Dec 6. doi: 10.1111/ejh.13367. [Epub ahead of print]

PMID:
31811682
3.

Educational intervention to optimise serum immunoglobulin test use in Irish primary care: an interrupted time series with segmented regression analysis.

Cadogan SL, Browne JP, Bradley CP, Fitzgerald AP, Cahill MR.

Br J Gen Pract. 2019 Oct 8. pii: bjgp19X706085. doi: 10.3399/bjgp19X706085. [Epub ahead of print]

PMID:
31594771
4.

CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.

O'Dwyer M, Henderson R, Naicker SD, Cahill MR, Murphy P, Mykytiv V, Quinn J, McEllistrim C, Krawczyk J, Walsh J, Lenihan E, Kenny T, Hernando A, Hirakata G, Parker I, Kinsella E, Gannon G, Natoni A, Lynch K, Ryan AE.

Blood Adv. 2019 Jun 25;3(12):1815-1825. doi: 10.1182/bloodadvances.2019000010.

5.

The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia.

Guo J, Luan X, Cong Z, Sun Y, Wang L, McKenna SL, Cahill MR, O'Driscoll CM.

J Control Release. 2018 Sep 28;286:154-166. doi: 10.1016/j.jconrel.2018.07.024. Epub 2018 Jul 29. Review.

PMID:
30016734
6.

Physician and practice characteristics associated with immunoglobulin test ordering.

Cadogan SL, Browne JP, Bradley CP, Fitzgerald AP, Cahill MR.

Fam Pract. 2018 Jan 16;35(1):41-46. doi: 10.1093/fampra/cmx063.

PMID:
28968810
7.

Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.

Appleby N, O'Brien D, Quinn FM, Smyth L, Kelly J, Parker I, Scott K, Cahill MR, Crotty G, Enright H, Hennessy B, Hodgson A, Leahy M, O'Leary H, O'Dwyer M, Hayat A, Vandenberghe EA.

Leuk Lymphoma. 2018 Jun;59(6):1338-1347. doi: 10.1080/10428194.2017.1376746. Epub 2017 Sep 19.

PMID:
28925785
8.

Oxidative Uranium Release from Anoxic Sediments under Diffusion-Limited Conditions.

Bone SE, Cahill MR, Jones ME, Fendorf S, Davis J, Williams KH, Bargar JR.

Environ Sci Technol. 2017 Oct 3;51(19):11039-11047. doi: 10.1021/acs.est.7b02241. Epub 2017 Sep 25.

PMID:
28876920
9.

Haemophagocytic lymphohistiocytosis presenting as HELLP syndrome: a diagnostic and therapeutic challenge.

Kerley RN, Kelly RM, Cahill MR, Kenny LC.

BMJ Case Rep. 2017 Apr 22;2017. pii: bcr-2017-219516. doi: 10.1136/bcr-2017-219516.

10.

Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.

Guo J, Russell EG, Darcy R, Cotter TG, McKenna SL, Cahill MR, O'Driscoll CM.

Mol Pharm. 2017 Mar 6;14(3):940-952. doi: 10.1021/acs.molpharmaceut.6b01150. Epub 2017 Feb 14.

PMID:
28146632
11.
12.

A novel 33-Gene targeted resequencing panel provides accurate, clinical-grade diagnosis and improves patient management for rare inherited anaemias.

Roy NB, Wilson EA, Henderson S, Wray K, Babbs C, Okoli S, Atoyebi W, Mixon A, Cahill MR, Carey P, Cullis J, Curtin J, Dreau H, Ferguson DJ, Gibson B, Hall G, Mason J, Morgan M, Proven M, Qureshi A, Sanchez Garcia J, Sirachainan N, Teo J, Tedgård U, Higgs D, Roberts D, Roberts I, Schuh A.

Br J Haematol. 2016 Oct;175(2):318-330. doi: 10.1111/bjh.14221. Epub 2016 Jul 19.

13.

CALR mutation profile in Irish patients with myeloproliferative neoplasms.

Haslam K, Conneally E, Flynn CM, Cahill MR, Gilligan O, O'Shea D, Langabeer SE.

Hematol Oncol Stem Cell Ther. 2016 Sep;9(3):112-5. doi: 10.1016/j.hemonc.2016.05.002. Epub 2016 Jun 23.

14.

The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.

O'Connor C, Lohan F, Campos J, Ohlsson E, Salomè M, Forde C, Artschwager R, Liskamp RM, Cahill MR, Kiely PA, Porse B, Keeshan K.

Oncogene. 2016 Oct 6;35(40):5272-5281. doi: 10.1038/onc.2016.66. Epub 2016 Mar 21.

PMID:
26996668
15.

The effectiveness of interventions to improve laboratory requesting patterns among primary care physicians: a systematic review.

Cadogan SL, Browne JP, Bradley CP, Cahill MR.

Implement Sci. 2015 Dec 5;10:167. doi: 10.1186/s13012-015-0356-4. Review.

16.

Ionizing radiation exposure as a result of diagnostic imaging in patients with lymphoma.

Crowley MP, O'Neill SB, Kevane B, O'Neill DC, Eustace JA, Cahill MR, Bird B, Maher MM, O'Regan K, O'Shea D.

Clin Transl Oncol. 2016 May;18(5):533-6. doi: 10.1007/s12094-015-1394-8. Epub 2015 Aug 26.

PMID:
26307754
17.

RNA interference for multiple myeloma therapy: targeting signal transduction pathways.

Guo J, McKenna SL, O'Dwyer ME, Cahill MR, O'Driscoll CM.

Expert Opin Ther Targets. 2016;20(1):107-21. doi: 10.1517/14728222.2015.1071355. Epub 2015 Jul 20. Review.

PMID:
26190583
18.

Smoking as an independent risk factor for macrocytosis in middle-aged adults: a population-based observational study.

O'Reilly MA, Millar SR, Buckley CM, Harrington JM, Perry IJ, Cahill MR.

Am J Hematol. 2015 Sep;90(9):E196-7. doi: 10.1002/ajh.24085. Epub 2015 Jul 22. No abstract available.

19.

Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation.

Orfali N, O'Donovan TR, Nyhan MJ, Britschgi A, Tschan MP, Cahill MR, Mongan NP, Gudas LJ, McKenna SL.

Exp Hematol. 2015 Sep;43(9):781-93.e2. doi: 10.1016/j.exphem.2015.04.012. Epub 2015 May 16.

20.

Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia.

Guo J, Cahill MR, McKenna SL, O'Driscoll CM.

Biotechnol Adv. 2014 Dec;32(8):1396-409. doi: 10.1016/j.biotechadv.2014.08.007. Epub 2014 Sep 16. Review.

PMID:
25218571
21.

Retinoid receptor signaling and autophagy in acute promyelocytic leukemia.

Orfali N, McKenna SL, Cahill MR, Gudas LJ, Mongan NP.

Exp Cell Res. 2014 May 15;324(1):1-12. doi: 10.1016/j.yexcr.2014.03.018. Epub 2014 Mar 30. Review.

22.

Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation.

Rishi L, Hannon M, Salomè M, Hasemann M, Frank AK, Campos J, Timoney J, O'Connor C, Cahill MR, Porse B, Keeshan K.

Blood. 2014 Apr 10;123(15):2389-400. doi: 10.1182/blood-2013-07-511683. Epub 2014 Feb 10.

PMID:
24516045
23.

Haematinic deficiency and macrocytosis in middle-aged and older adults.

McNamee T, Hyland T, Harrington J, Cadogan S, Honari B, Perera K, Fitzgerald AP, Perry IJ, Cahill MR.

PLoS One. 2013 Nov 7;8(11):e77743. doi: 10.1371/journal.pone.0077743. eCollection 2013.

24.

A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.

Maung SW, Leahy M, O'Leary HM, Khan I, Cahill MR, Gilligan O, Murphy P, McPherson S, Jackson F, Ryan M, Hennessy B, McHugh J, Goodyer M, Bacon L, O'Gorman P, Nee A, O'Dwyer M, Enright H, Saunders J, O'Keeffe D.

Br J Haematol. 2013 Oct;163(1):118-22. doi: 10.1111/bjh.12486. Epub 2013 Aug 2.

PMID:
23909468
25.

Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.

Elzinga BM, Nyhan MJ, Crowley LC, O'Donovan TR, Cahill MR, McKenna SL.

Am J Hematol. 2013 Jun;88(6):455-62. doi: 10.1002/ajh.23428. Epub 2013 Apr 2.

26.

Phase I/II safety study of transfusion of prion-filtered red cell concentrates in transfusion-dependent patients.

Cahill MR, Murphy T, Khan M, Fagan J, Murphy WG.

Vox Sang. 2010 Aug 1;99(2):174-6. doi: 10.1111/j.1423-0410.2010.01330.x. Epub 2010 Mar 22.

PMID:
20345513
27.

Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.

Langabeer SE, Crampe M, Haslam K, Kelly J, Cahill MR.

Leuk Res. 2010 Jul;34(7):e176-7. doi: 10.1016/j.leukres.2010.01.025. Epub 2010 Feb 12. No abstract available.

PMID:
20153526
28.

Can mean platelet component be used as an index of platelet activity in stable coronary artery disease?

Cooke J, Murphy T, McFadden E, O'Reilly M, Cahill MR.

Hematology. 2009 Apr;14(2):111-4. doi: 10.1179/102453309X385160.

PMID:
19298724
29.

Writing to patients: a randomised controlled trial.

O'Reilly M, Cahill MR, Perry IJ.

Clin Med (Lond). 2006 Mar-Apr;6(2):178-82.

30.

The issue of anti-D: an integrated seamless approach from recognition of need to bedside administration.

Ryan MJ, Joyce S, O'Brien N, Lynch E, Burke G, Cahill MR.

Ir J Med Sci. 2005 Jul-Sep;174(3):58-63.

PMID:
16285341
31.

Detection of aspirin resistance by PFA-100: prevalence and aspirin compliance in patients with chronic stable angina.

Crowe B, Abbas S, Meany B, de Haan J, Cahill MR.

Semin Thromb Hemost. 2005;31(4):420-5.

PMID:
16149020
32.

Duration of increased bleeding tendency after cessation of aspirin therapy.

Cahill RA, McGreal GT, Crowe BH, Ryan DA, Manning BJ, Cahill MR, Redmond HP.

J Am Coll Surg. 2005 Apr;200(4):564-73; quiz A59-61.

PMID:
15804471
33.

Haemovigilance is associated with decreased use and improved appropriateness of blood transfusion.

Cahill MR, Joyce S, O'Brien N, Casey M.

Vox Sang. 2003 Aug;85(2):121-2. No abstract available.

PMID:
12925167
34.

P-selectin and glycoprotein 53 expression in myeloproliferative disorders.

Cahill MR.

Br J Haematol. 2001 Jan;112(1):253. No abstract available.

PMID:
11225605
35.

The rational use of platelet transfusions in children.

Cahill MR, Lilleyman JS.

Semin Thromb Hemost. 1998;24(6):567-75. Review.

PMID:
10066152
36.

Adhesion molecules in clinical medicine.

Cavenagh JD, Cahill MR, Kelsey SM.

Crit Rev Clin Lab Sci. 1998 Sep;35(5):415-59. Review.

PMID:
9791747
37.
38.

Inflammation, aspirin, and the risk of cardiovascular disease.

Cahill MR, Perry IJ.

N Engl J Med. 1997 Aug 7;337(6):422-3; author reply 423-4. No abstract available.

PMID:
9244847
39.

Is it refractory idiopathic thrombocytopenic purpura?

Cahill MR, Newland AC.

Lancet. 1997 Apr 12;349(9058):1066. No abstract available.

PMID:
9107246
40.

Haemophilia.

Cahill MR, Colvin BT.

Postgrad Med J. 1997 Apr;73(858):201-6. Review.

41.

Current Practice in the Treatment of Haemophilia.

Cahill MR, Colvin BT.

Hematology. 1997;2(5):351-8. doi: 10.1080/10245332.1997.11746355.

PMID:
27405401
42.

Clinical significance of platelet size in inflammatory bowel disease?

Collins CE, Cahill MR, Rampton DS.

Thromb Haemost. 1997 Jan;77(1):218-9. No abstract available.

PMID:
9031479
43.

Correlation of GP53 and P-selectin expression in myeloproliferative disorders and normal controls.

Cahill MR, Macey MG, Newland AC.

Blood Coagul Fibrinolysis. 1996 Mar;7(2):169-71.

PMID:
8735810
44.
45.

Treatment of acute myeloid leukaemia in pregnancy.

Cavenagh JD, Richardson DS, Cahill MR, Bernard T, Kelsey SM, Newland AC.

Lancet. 1995 Aug 12;346(8972):441-2. No abstract available.

PMID:
7542722
46.

Implementation of a nurse practitioner policy for the requisition and administration of drugs in a haemophilia comprehensive care centre.

Cahill MR, Woosey CP, Hayden SM, Mac Clean M, Colvin BT.

Haemophilia. 1995 Jul;1(3):172-4. doi: 10.1111/j.1365-2516.1995.tb00062.x.

PMID:
27214534
47.

Effect of fixation on quantification of the expression of leucocyte function-associated surface antigens.

McCarthy DA, Macey MG, Cahill MR, Newland AC.

Cytometry. 1994 Sep 1;17(1):39-49.

48.

Prevention of restenosis after angioplasty.

Cahill MR, Macey MG, Dawson JR, Newland AC.

Lancet. 1994 May 28;343(8909):1361. No abstract available.

PMID:
7910347
49.

Platelets circulate in an activated state in inflammatory bowel disease.

Collins CE, Cahill MR, Newland AC, Rampton DS.

Gastroenterology. 1994 Apr;106(4):840-5.

PMID:
8143990
50.

Platelet activation in coronary artery disease.

Cahill MR, Newland AC.

Br J Biomed Sci. 1993 Sep;50(3):221-34. Review.

PMID:
8241838

Supplemental Content

Loading ...
Support Center